Time To Efficacy and Onset Of Action Of Linezolid

This study has been completed.
Sponsor:
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT00147511
First received: September 2, 2005
Last updated: May 9, 2011
Last verified: May 2011
  Purpose

To assess the onset of action of linezolid


Condition Intervention Phase
Gram-Positive Bacterial Infections
Skin and Connective Tissue Diseases
Drug: linezolid
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Time To Efficacy and Onset Of Action Of Linezolid In Skin and Soft Tissue Infections

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Time to defervescence

Secondary Outcome Measures:
  • Reduction of CRP levels Reduction of leucocyte count

Enrollment: 118
Study Start Date: June 2003
Study Completion Date: June 2005
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • suspected grampositive infection
  • fever > 38 C

Exclusion Criteria:

  • Infections to be treated successfully by surgical procedures
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00147511

Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

No publications provided

Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer
ClinicalTrials.gov Identifier: NCT00147511     History of Changes
Other Study ID Numbers: OXAA-0026-162
Study First Received: September 2, 2005
Last Updated: May 9, 2011
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Additional relevant MeSH terms:
Bacterial Infections
Connective Tissue Diseases
Gram-Positive Bacterial Infections
Soft Tissue Infections
Infection
Linezolid
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Protein Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on April 17, 2014